Table III. Treatment responses of evaluable patients.
CI: Confidence interval; CR: complete response; ICI: immune checkpoint inhibitor; PD: progressive disease; PR: partial response; SD: stable disease; TI: paclitaxel-ifosfamide. aOne of the evaluable patients received paclitaxel-ifosfamide in combination with pembrolizumab and lenvatinib, and the best response was PD.
